dextromethorphan/quinidine

Phase 3Small molecule

TThe University of Texas Health Science Center, Houston

dextromethorphan/quinidine is one of 19 small molecule programs targeting Irritability. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IrritabilityActive, not recruiting

IrritabilityPhase 3

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Irritability

#DrugCompanyPhaseTrials

Robitussin

Pfizer

Approved

1 2

Aricept

Eisai

Approved

—3

Calciferol

Alnylam Pharmaceuticals

Approved

—4

Chantix

PPrism Pharmaceuticals

Approved

1 5

Abilify

Otsuka

Approved

1 6

Prometrium

Ferring

Approved

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Risperdal

1 9

Karx-EC

Karxt

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depression1 trial

Nuedexta in Treatment-Resistant Major Depression

Completed·JJames Murrough·Phase 2·NCT01882829·20 enrolled

Irritability1 trial

Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease

Completed·TThe University of Texas Health Science Center, Houston·Phase 3·NCT03854019·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for dextromethorphan/quinidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dextromethorphan/quinidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dextromethorphan/quinidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center, Houston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe University of Texas Health Science Center, Houston

dextromethorphan/quinidine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Major Depression1 trial

Irritability1 trial

References

Drug Info

Quick Facts

Related News